0000899243-19-002330.txt : 20190201 0000899243-19-002330.hdr.sgml : 20190201 20190201164243 ACCESSION NUMBER: 0000899243-19-002330 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190131 FILED AS OF DATE: 20190201 DATE AS OF CHANGE: 20190201 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Edick Paul R CENTRAL INDEX KEY: 0001531178 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38536 FILM NUMBER: 19560345 MAIL ADDRESS: STREET 1: C/O NEWLINK GENETICS CORP. STREET 2: 2503 SOUTH LOOP DR., SUITE 5100 CITY: AMES STATE: IA ZIP: 50010 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: XERIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001346302 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 203352427 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 180 NORTH LASALLE STREET STREET 2: STE 1800 CITY: CHICAGO STATE: IL ZIP: 60601 BUSINESS PHONE: 512-498-2670 MAIL ADDRESS: STREET 1: 180 NORTH LASALLE STREET STREET 2: STE 1800 CITY: CHICAGO STATE: IL ZIP: 60601 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-01-31 0 0001346302 XERIS PHARMACEUTICALS INC XERS 0001531178 Edick Paul R C/O XERIS PHARMACEUTICALS, INC. 180 N. LASALLE STREET, SUITE 1810 CHICAGO IL 60601 1 1 0 0 See Remarks Common Stock 2019-01-31 4 A 0 125000 0.00 A 125000 D Common Stock 13430 I By: Paul R. Edick 2008 Revocable Trust u/d/t dated 6/25/2018 Stock Option (right to buy) 13.88 2019-01-31 4 A 0 200000 0.00 A 2029-01-31 Common Stock 200000 200000 D These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. 25% of these restricted stock units shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. 25% of these shares shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. Chairman, President & Chief Executive Officer /s/ Beth Hecht, as Attorney-in-Fact 2019-02-01